Vaccine against gonorrhoea to roll out in Scotland
The illness, which is the second most common sexually transmitted infection (STI) in Scotland is potentially painful and in rare cases can be life-threatening.
Scottish cases have risen in recent years, with 5,999 infections in 2023 - a rise of 59% from before the Covid pandemic.
Those eligible for the vaccine will include gay and bisexual men at highest risk of infection, as well those involved in selling or exchanging sex, regardless of their gender.
Syphilis and drug-resistant gonorrhoea increasing
World-first gonorrhoea vaccine launched by NHS England as infections soar
Doctors and charities call for gonorrhoea vaccine roll-out
Those most affected by gonorrhoea in the UK are those aged 16 to 25, gay and bisexual men, and those of black and Caribbean ancestry.
The vaccine, which is 30-40% effective, is also being delivered in England and Northern Ireland.
Doctors and charities called for vaccinations earlier this year after the UK's Joint Committee on Vaccination and Immunisation (JCVI) recommended a targeted roll-out in November 2023.
The Scottish government is funding the vaccination programme north of the border.
Public Health Minister Jenny Minto said the campaign was "urgent and timely since the number of diagnoses has been high and the disease is becoming increasingly difficult to treat with antibiotics".
She added: "The science tells us that this vaccine will potentially protect thousands of people and prevent the spread of infection.
"Anything which stops people from contracting gonorrhoea in the first place can have huge benefits, including ensuring our health system remains resilient by reducing the amount of treatment needed."
Dr Sam Ghebrehewet, head of the vaccination and immunisation division at Public Health Scotland, said the jab was a "welcome new intervention".
He said: "This vaccination programme is expected to help control and prevent the spread of gonorrhoea.
"Public Health Scotland is working with the Scottish government and colleagues across NHS boards to finalise plans for the rollout of this targeted vaccination, offering to those at increased risk of gonorrhoea from August 2025."
The vaccine was not designed for gonorrhoea - it is the meningitis B vaccine currently given to babies.
The bacteria that cause the two diseases are so closely related that the MenB jab appears to cut gonorrhoea cases by around a third.
However, it will not eliminate the risk of catching gonorrhoea - it is normally caught while having sex without a condom.
Prof Andrew Pollard, the chair of the JCVI which recommended the vaccine, said despite it only being 30% effective, it was "worth having" and could have "a huge impact" overall.
Gonorrhoea is also becoming increasingly difficult to treat.
Most cases are treated with a single dose of antibiotics, but there is an 80-year history of the bacterium which causes gonorrhoea repeatedly evolving resistance to antibiotics.
This is also happening to current treatments and is why some doctors are concerned gonorrhoea could one day become untreatable.
They say the best way to deal with a drug-resistant infection is to never catch it in the first place.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Phone notes made by trans doctor after nurse dispute were edited, tribunal told
Phone notes made by a transgender doctor following a dispute with a nurse had been edited, a tribunal has heard. An employment tribunal was told on Friday that NHS Fife did not commission a forensic or in-person examination of Dr Beth Upton's phone in May 2025. The health board's security analyst 'did not have a technical answer' for discrepancies on dates on Google Notes made by Dr Upton, the tribunal heard. Sandie Peggie was suspended after she complained about having to share a changing room with Dr Upton at Victoria Hospital in Kirkcaldy, Fife, on Christmas Eve 2023. The nurse was placed on special leave after Dr Upton made an allegation of bullying and harassment and cited concerns about 'patient care'. Ms Peggie has lodged a claim against NHS Fife and Dr Upton, citing the Equality Act 2010, including sexual harassment; harassment related to a protected belief; indirect discrimination; and victimisation. The tribunal heard entries on Google Notes had 'discrepancies' between the date of editing and date of creation. Independent IT expert Jim Borwick, director of KJB Computer Forensics Consultancy, was commissioned by Ms Peggie's representatives and agreed he was suggesting the doctor 'was trying to mislead' the tribunal. In a report, Mr Borwick wrote 'Dr Upton is silent on fact that Notes can be rearranged with relative ease', and that he was 'perplexed' and 'at a loss' as to how the discrepancies had occurred, and was told 'notes did not include patient care allegations Dr Upton made about Ms Peggie', the tribunal heard. One note from December 18, 2023 logged 'working nights, won't make eye contact, won't acknowledge my presence, haven't had direct conversation but can feel the dismissal/hostility', which was edited on December 26 at 1.21am, the tribunal heard. Mr Borwick said: 'In addition to text on that date, this had been added so it is not contemporaneous.' He confirmed he was 'suggesting that Dr Upton is trying to mislead the tribunal', when asked by Jane Russell KC, representing NHS Fife and Dr Upton. Ms Russell said: 'When you said Dr Upton is silent on fact that notes can be rearranged, you're suggesting that Dr Upton is trying to mislead the tribunal?' The IT expert said: 'I suppose that's my comment, yes.' Ms Russell asked if he had been instructed 'to come up with explanation that there were lies on the part of Dr Upton' and to 'undermine Dr Upton's account of patient care allegations'? The witness said: 'I don't think we were trying to undermine anything, it was just a case of trying to look at these notes.' He added: 'I was told to recover notes about patient care allegations; no reason was given, just to recover those notes.' He suggested a Teams meeting should have been recorded, and that screenshots could have been 'superimposed' on notes. Ms Russell said in one screenshot 'the conundrum is that the edited date predates the created date', and asked if 'the only explanation for discrepancy is that Dr Upton is lying about creation dates'. The witness said: 'I can't recreate this, Mr Donaldson [Peter Donaldson, information security manager for NHS Fife] can't; this can't happen. It just can't happen that way.' However, Ms Peggie's junior counsel, Charlotte Elves, said she was 'astonished' at a suggestion that anyone 'would have instructed an expert to lie, or that an expert would accept such instructions'. The tribunal heard a note titled 'weird incident 26.08.23' was timestamped showing it was created on October 26, 2023, according to Google. The tribunal also heard evidence that Dr Upton was remotely supervised at one point during a Teams call by Mr Donaldson. Giving evidence, Mr Donaldson said: 'I don't believe Dr Upton was trying to mislead us in any way. 'I completely agree this is how Google presents; on the face of it the October date is the earliest date. I don't dispute that. The notes supplementary to that are the same.' Ms Elves said: 'This quandary that we've got about creation on October 26, as I understand it, there's no understandable technical explanation?' Mr Donaldson said: 'Not that I'm aware of.' Ms Elves said: 'You say you don't believe Dr Upton was trying to mislead the tribunal but presumably accept that is one explanation for this inexplicable phenomenon?' The witness said: 'It is a possibility but I don't believe that's the case.' Ms Elves said: 'Going back to apparent difficulty with the screenshots, I think you told the tribunal that you can't fathom any technological explanation; do you accept that one explanation for images that purport to show the inexplicable is they have been manipulated?' Mr Donaldson said: 'I can't say it's impossible.' The tribunal continues.
Medscape
12 minutes ago
- Medscape
EMA Launches Review of Tecovirimat Effectiveness for Mpox
The European Medicines Agency (EMA) has initiated a review of Tecovirimat SIGA, also called TPOXX, a medicine used to treat mpox. This follows emerging clinical trial data suggesting a lack of effectiveness. The mpox virus is an orthopoxvirus, a class that includes the smallpox virus. Tecovirimat SIGA was originally approved in the US to treat smallpox. The EMA and the Medicines and Healthcare products Regulatory Agency in the UK authorized its use in January 2022, at the start of an mpox outbreak in Europe, for the treatment of smallpox, mpox, cowpox, and vaccinia complications following smallpox vaccination, in adults and children weighing at least 13 kg. The drug is an oral medicine that interferes with a protein called VP37 found on the surface of orthopoxviruses, preventing them from reproducing normally and thus slowing the spread of infection. No other treatments are authorized for mpox or cowpox infections, which may in rare cases be fatal. European Cases Linked With Risky Sexual Behaviors Mpox is a zoonotic infection occurring mainly in West and Central Africa, with most cases in Europe before 2022 either imported from countries where mpox is endemic or from contacts with documented epidemiological links to imported cases. The outbreak in the EU and UK has been transmitted between humans mainly through sexual contact. It primarily affects gay, bisexual, or other men who have sex with men and who have multiple sexual partners, participate in group sex, or attend sex-on-premises venues. Transmission occurs primarily within interconnected sexual networks. Symptoms of mpox typically appear 1-3 weeks after infection and include fever, headache, chills, physical weakness, lymph node swelling, back pain, and muscle aches, along with a distinct, fast-spreading papular rash on the skin and mucosal sores in the mouth, nose, throat, or digestive tract that then turn into fluid-filled vesicles. Mild-to-moderate symptoms usually last 2-4 weeks and are followed by full recovery, though some people develop permanent scars. During outbreaks, the case fatality of mpox ranges from 0% to 11%. People who are immunocompromised, including those with HIV infection or AIDS, are at a higher risk for severe disease. Exceptional Circumstances Approval During Outbreak Approval for Tecovirimat SIGA was granted under 'exceptional circumstances' provisions, based only on pharmacodynamic and pharmacokinetic studies, because the disease is rare and sporadic, so human studies were not available. A condition of such authorization is that the company marketing Tecovirimat SIGA is required to provide an annual update on benefits and risks. The EMA's review is a postauthorization procedure that involves a scientific assessment by the agency on behalf of the EU aimed at resolving issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In the case of Tecovirimat SIGA (tecovirimat), the review was initiated at the request of the European Commission. The review follows publication of preliminary results from two clinical trials. In the randomized, placebo-controlled PALM007 trial involving 597 children and adults with laboratory-confirmed clade I mpox in the Democratic Republic of the Congo (DRC), results reported in April in The New England Journal of Medicine showed that the drug did not reduce the duration of mpox lesions (median time to resolution, 7 vs 8 days). The overall mortality among enrollees, regardless of whether or not they received the drug, was 1.6% — much lower than that generally reported in the DRC, but this was attributed to hospitalization and high-quality supportive care within the trial. The other trial, STOMP, involved people from multiple countries with mild-to-moderate laboratory-confirmed or presumptive clade II mpox. Again, the active drug did not demonstrate efficacy in time to skin and mucosal lesion resolution compared with placebo. The EMA said that similar results had recently been obtained from another study, UNITY, which also did not indicate faster skin lesion resolution on tecovirimat compared with placebo. Further analyses from ongoing or recently completed studies are still awaited and will also inform the EMA's final assessment.
Medscape
12 minutes ago
- Medscape
EMA OKs Oral Treatment for Postnatal Depression
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a positive opinion on zuranolone (Zurzuvae, Biogen Netherlands BV), the first oral drug to treat postpartum depression in adults. Marketing authorization was granted in recognition of clinical trial results showing a reduction in postpartum depressive symptoms after 2 weeks' treatment. Zuranolone is a neuroactive steroid that enhances the activity of the neurotransmitter gamma-aminobutyric acid (GABA). It is thought to exert antidepressant effects by enhancing GABAergic inhibition. In a multicenter, randomized, double-blind, placebo-controlled study, zuranolone at a 50 mg dose was given for 14 days to women who met the Diagnostic and Statistical Manual of Mental Disorders criteria for a major depressive episode of postpartum depression and whose symptoms started in the third trimester or within 4 weeks of delivery. Compared with placebo, the active group demonstrated significantly greater symptom improvement on days 3,15 (the primary endpoint), and 45, using the standard 17-item Hamilton rating scale for depression. The FDA approved the drug in August 2023, at which time it was the first oral treatment for postpartum depression, with previous therapies requiring intravenous dosing. It is available in 20 mg, 25 mg, and 30 mg capsules. The most common side effects are somnolence, dizziness, confusion, trouble walking, and sedation. Patients are advised to avoid alcohol and not to drive, operate machinery, or undertake other dangerous activities until at least 12 hours after taking each dose during the 14-day treatment course. There may also be an increased risk of suicidal thoughts and actions in people 24 years of age and younger. Animal studies have suggested a possible risk of teratogenic effects, so women who may become pregnant are advised to use effective contraception during treatment and for 1 week after the final dose, and to alert their healthcare provider should they become pregnant during treatment. The EMA said that detailed recommendations will be described in the summary of product characteristics, which will be published on the EMA website in all official European Union languages after the marketing authorization has been granted by the European Commission. Perinatal Mental Healthcare 'in Its Infancy' In Western countries, postpartum depression is estimated to affect between 10% and 15% of women during the first year after birth , with substantial differences in rates depending on socioeconomic factors such as marital status, educational level, social support, spouse care, violence, gestational age, breast feeding, child mortality, financial difficulties, partnership, life stress, smoking, alcohol intake, and living conditions. Common symptoms include feelings of desperation, sadness, anxiety, irritability, and isolation, as well as nausea, changes in sleep and eating habits, decreased libido, crying spells, mental lability, thoughts of hurting oneself and/or the infant, and suicidal ideation. The condition can wreak havoc on women's mental health as well as that of their partners. It can impair the parental relationship, the mother-child bond, and the emotional and cognitive growth of infants, with potential long-term effects. Postnatal depression may occur alongside post-traumatic stress disorder following stressful or traumatic childbirth experiences . Yet a review published in Frontiers in Psychiatry last year suggested that fewer than half of countries in the World Health Organization (WHO) European region had policies specifically on perinatal mental health, leading its authors to conclude that "perinatal mental health care is in its infancy in most WHO European countries."
